News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental HIV treatments news

Show

From To
New and experimental HIV treatments
Stribild (a.k.a. "Quad") Performs Well for People Over 50, Study Finds

Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir) performs similarly among people over 50 years old as with younger people, according to the results of a two-study sub-analysis presented at ICAAC 2012. The presentation marks part of an emerging trend in research that reflects the aging of the HIV-infected population in the U.S., and the need for more studies on antiretrovirals specifically within older groups.

Published
24 September 2012
From
The Body
Health services and systems
South Africa to open US$8 million HIV, TB facility

The KwaZulu-Natal Research Institute for Tuberculosis and HIV (K-RITH) will open a 40,000 square feet research building in Durban, South Africa, next month (October) — the latest example of a trend of pouring investment into fighting Africa's HIV epidemic, according to experts.

Published
21 September 2012
From
SciDevNet
New and experimental HIV treatments
Avexa’s HIV integrase inhibitors show activity against drug-resistant HIV with potential for once-daily dosing

Australian biotechnology company Avexa Limited [ASX:AVX] today announced that test results from an independent laboratory in the USA have confirmed the activity of Avexa’s proprietary new generation HIV integrase inhibitors against resistant Human Immunodeficiency Virus (HIV).

Published
20 September 2012
From
Avexa press release
Treatment guidelines
Stribild Receives ‘Alternative’ U.S. Guidelines Ranking

U.S. HIV treatment guidelines classify Stribild, formerly known as the Quad, as an 'alternative' regimen option for first-time treatment takers. 

Published
19 September 2012
From
AIDSMeds
New and experimental HIV treatments
HIV Drug Consortium Wins €4M EU Funding

The project, known as HIVINNOV, is being coordinated by Mutabilis and aims to develop a class of antiretrovirals that don’t target HIV directly, but rather impact on the interactions between virus and host.

Published
18 September 2012
From
Genetic Engineering News
Pharmaceutical industry
Gilead's HIV pill could be market leader in 3-5 years: JP Morgan

J.P. Morgan Securities raised its price target on Gilead Sciences Inc to $75 from $70, saying the company's new HIV pill Stribild could emerge as a "market leader" in three to five years, sending the drugmaker's shares to a life-high.

Published
18 September 2012
From
CNBC
New and experimental HIV treatments
Long-acting integrase inhibitor S/GSK1265744 active against multiple HIV subtypes

The integrase inhibitor S/GSK1265744 exhibited potent and prolonged activity against a broad range of HIV subtypes, was active against clones with resistance to raltegravir (Isentress) and elvitegravir, and

Published
17 September 2012
By
Liz Highleyman
New and experimental HIV treatments
Dolutegravir combo beats Atripla for effectiveness and tolerability

The experimental integrase inhibitor dolutegravir combined with abacavir/lamivudine (Kivexa or Epzicom) demonstrated statistically superior antiviral efficacy than the popular Atripla single-tablet regimen for first-line HIV treatment, largely because fewer people

Published
14 September 2012
By
Liz Highleyman
New and experimental HIV treatments
New HIV Drugs Promising but Unworkable

A new series of nucleotide competing reverse transcriptase inhibitors (NcRTIs) may represent a novel treatment option for HIV-1 infected patients but may be limited by toxicity given early animal data.

Published
14 September 2012
From
MedPage Today
New and experimental HIV treatments
Long-Lasting HIV Drug Could Change Therapy

An extremely long-lasting anti-HIV drug has the potential to alter both treatment and prevention of the virus, researchers said at the annual Interscience Conference on Antimicrobial Agents and Chemotherapy. The investigational integrase inhibitor S/GSK744 might need to be given only every 3 months.

Published
13 September 2012
From
MedPage Today
← Prev1...34567...66Next →

Filter by country